PX91.F Cassava Sciences Inc
- Market cap
- EUR 20.9M
- P/E
- -
- P/B
- 0.41x
- ROE
- -68.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PX91.F undervalued?
Graham numberThe Graham number of Cassava Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cassava Sciences Inc fundamental analysis
No fundamental analysis for Cassava Sciences Inc yet.
Cassava Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, In…
Full company profileCassava Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cassava Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.0M | -11.9M | -6.66M | -4.96M | -6.79M | -32.9M | -80.0M | -107M | -142M | -96.1M | -42.4M |
| EBITDA | - | -11.9M | -6.59M | -4.90M | -6.77M | - | -80.2M | -106M | -141M | -95.2M | -41.5M |
| Net Income | -14.9M | -11.9M | -6.56M | -4.63M | -6.33M | -32.4M | -76.2M | -97.2M | -24.3M | -91.0M | -39.5M |
| EPS | - | -1.81 | -0.38 | -0.21 | -0.18 | -0.81 | -1.83 | -2.30 | -0.50 | -1.88 | -0.79 |
| Balance Sheet | |||||||||||
| Total Assets | 19.3M | 10.8M | 20.1M | 23.5M | 94.3M | 267M | 235M | 152M | 158M | 118M | 100M |
| Total Liabilities | 665K | 1.13M | 511K | 1.39M | 2.10M | 12.9M | 7.30M | 14.2M | 11.8M | 44.0M | 42.1M |
| Shareholders' Equity | 18.6M | 9.70M | 19.6M | 22.1M | 92.2M | 254M | 228M | 137M | 146M | 74.4M | 58.0M |
| Cash & Short-term Investments | 16.6M | 10.5M | 19.8M | 23.1M | 93.5M | 233M | 201M | 121M | 129M | 95.5M | 47.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.2M | -8.24M | -4.77M | -2.51M | -5.38M | -30.2M | -77.5M | -82.0M | -117M | -32.3M | -25.1M |
| Capital Expenditure | 75.0K | 18.0K | 18.0K | 18.0K | 22.2M | 22.2M | 2.71M | 414K | 103K | 581K | 41.3K |
| Free Cash Flow | - | -8.24M | -4.77M | -2.53M | -5.38M | -52.4M | -80.2M | -82.4M | -117M | -32.8M | -25.2M |
| Ratios | |||||||||||
| ROE | -79.7% | -122.8% | -33.4% | -21.0% | -6.9% | -12.8% | -33.5% | -70.7% | -16.7% | -122.3% | -68.2% |
| ROA | -76.9% | -110.0% | -32.6% | -19.7% | -6.7% | -12.1% | -32.5% | -64.1% | -15.5% | -76.9% | -39.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Cassava Sciences Inc dividends
Cassava Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on May 10, 2017.
Who owns Cassava Sciences Inc
- Insiders 1.97%
- Institutions 25.19%
- Public & others 72.84%
- Shares outstanding 50.3M
- Free float 48.8M
Cassava Sciences Inc company profile
- Company name
- Cassava Sciences Inc
- Ticker
- PX91.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
- Phone
- 512 501 2444
- Website
- filanatx.com
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences Inc management
10- Mr. Richard Jon BarryCEO, President & Director · born 1959
- Mr. Eric J. SchoenChief Financial Officer · born 1968
- Mr. R. Christopher Cook J.D.Chief Operating & Legal Officer · born 1964
- Dr. George Thornton Ph.D.Senior Vice President of Technology
- Mr. Michael ZamlootSenior Vice President of Technical Operations
- Jaren LandenChief Clinical Development Officer
- Dr. Angelique Bordey Ph.D.Senior Vice President of Neuroscience
- Mr. Jack Moore Ph.D.Senior Vice President of Clinical Development
- Dr. Joseph Hulihan M.D.Chief Medical Officer · born 1956
- Ms. Nancy TeasdaleHead of Regulatory Affairs